Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnings Per Share by Approximately $0.25 in 2026 and Approximately $0.60 in 2027 –– Exercises Option to ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...

Physical Properties Testers Group Limited ("PPT" or the "Company"), a global leader in physical property test and measurement solutions, announced today the appointment of Mark Fleiner as its new ...

The annual J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' ...

Ecer.com states that the application of AI in foreign trade has evolved from a tool-assisted approach to full-process ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

North American supply growth, cost cuts, and NAL expansion driving 2026 profitability inflection. Click here to read more.

For the fiscal year ending January 31, 2027, management expects revenues in the range of $1.38 billion to $1.41 billion with Adjusted EBITDA margin of 43.8% to 44.3% and a yield on HSA Cash of ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...

Discover how gross profit and operating income differ and why both are crucial in assessing a company’s financial health. Get ...

The Plunge Protection Team, also known as the Working Group on Financial Markets, advises the U.S. president on maintaining ...